We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




University of Pittsburgh Medical Center

By HospiMedica staff writers
Posted on 13 Apr 2004
Two companies have agreed to team up to select, validate, and usher novel biomarkers from preclinical trials to the commercialization stage, while offering pharmaceutical companies full testing services from early-stage trials through drug launches.

DakoCytomation (Copenhagen, Denmark) and Pathogenesys (Irvine, CA, USA) announced the agreement at the meeting of the American Association for Cancer Research in Orlando (FL, USA) in March 2004.

DakoCytomation pioneered the concept of pharmacodiagnostics when the company developed the Hercep Test, the first clinical test to assess patients for a specific targeted therapy. More...
Recently, the company received regulatory approval from Switzerland and the U.S. Food and Drug Administration (FDA) for the use of its epidermal growth factor receptor (EGFR) pharmDx kit as an aid in identifying colorectal cancer patients eligible for treatment with cetuximab (Erbitux).

"As a diagnostic company with two pharmDx kits already in routine clinical use, we have proven expertise with regulatory issues, manufacturing, and commercialization,” said Dennis Chenoweth, corporate vice president of diagnostics for DakoCytomation.

Under the agreement, Pathogenesys will provide preclinical support through phase III to pharmaceutical partners leveraging off DakoCytomation's products and services. DakoCytomation will focus its global resources on developing, manufacturing, obtaining regulatory approvals, and commercializing companion diagnostic tests.

"We are excited to partner with a company that will help us achieve the goal of improving the lives of cancer patients,” said James Thompson, M.D., CEO and medical director of Pathogenesys.




Related Links:
DakoCytomation
Pathogenesys

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Syringe Pump
SP50 Series
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.